リキッドバイオプシー市場：バイオマーカー、サンプル、タイプ、技術、適応症、エンドユーザー、用途別-2025～2030年世界予測

リキッドバイオプシー市場は、2023年に60億米ドルと評価され、2024年には67億2,000万米ドル、CAGR 12.19%で成長し、2030年には134億4,000万米ドルに達すると予測されています。

リキッドバイオプシーは、診断検査と個別化された患者ケアの状況を根本的に再定義しました。近年、非侵襲的診断法の革新により、疾患、特にがんの発見とモニタリングの方法に変革がもたらされつつあります。血液を中心とした非固形生体組織のサンプリングと分析に依存するこの方法は、従来の外科的生検に代わる実行可能な選択肢を提供するものです。リキッドバイオプシー技術の進化は、病態に関するリアルタイム情報を提供し、タイムリーで的を絞った治療介入を可能にする循環バイオマーカーを捕捉する能力によって推進されています。

科学界は、この技術を活用して従来の組織生検の限界を克服し、早期発見を強化し、継続的なモニタリングを容易にすることへの関心を高めています。研究開発への投資の増大と高精度分析ツールの統合により、リキッドバイオプシー市場は現在、臨床ニーズと技術進歩の収束点に立っています。リキッドバイオプシーは腫瘍学への応用に加え、より包括的な診断ソリューションを可能にするため、他の医療セグメントにも急速にその裾野を広げつつあります。本分析では、市場の現状を詳細に調査し、動向、セグメンテーション、地域別洞察、この技術革新を推進する主要企業を明らかにします。

リキッドバイオプシーをめぐる情勢の変化

リキッドバイオプシー市場は、技術の進歩、規制枠組みの進化、低侵襲診断手技の需要増に後押しされ、急速な変貌を遂げています。ここ数年の間に、従来の方法から、より高い精度、より迅速なターンアラウンドタイム、より広範な適用性を提供するソリューションへの明確なシフトが起こっています。高性能・シーケンス、データ分析、自動化の進歩は、検査結果の感度と特異度を向上させただけでなく、処置の費用対効果も高めました。

産業の利害関係者は、ダイナミックな遺伝子とエピジェネティックな変化を捉えるリキッドバイオプシーの能力を活用しようとして、これらの変化を受け入れています。この変化は、バイオマーカー探索と検証プロセスの改良を目的とした、研究機関、技術プロバイダ、医療従事者間の積極的な共同研究によって顕著に表れています。さらに、規制経路の合理化により、臨床現場への新規ツールやアッセイの導入がさらに加速しています。市場導入が拡大するにつれ、競合情勢も拡大し、継続的な技術革新と多セグメントの専門知識の統合が不可欠な環境が続いています。リキッドバイオプシーを取り巻く現在の機運は、臨床診断における標準的な実践としてプレシジョン・メディシンを採用するという広範な傾向を示しており、最終的には医療システム全体における患者転帰の改善とコスト効率化に貢献します。

市場セグメンテーションによる主要市場概要

リキッドバイオプシー市場を詳細にセグメント化すると、疾患検出と管理への多様なアプローチを支える複雑な構造が明らかになります。分析の中核の一つはバイオマーカーによるもので、無細胞DNA、循環腫瘍細胞、循環腫瘍DNA、細胞外小胞の重要性を強調しています。このバイオマーカーによるセグメンテーションは、多様な診断能力を強調するだけでなく、各マーカーが提供する特定の分子的洞察を強調します。同様に重要なのは、サンプルタイプによるセグメンテーションです。この市場は、血液ベースと尿ベースのサンプルを利用する方法論にわたって調査されており、利便性と臨床効果の両方をサポートしています。

さらに、市場は提供される製品やサービスのタイプによって分類され、アッセイキット、機器、サービスが含まれます。同様に重要なのは、技術によるセグメンテーションであり、NGSを用いたマルチジーンパラレル分析やPCRマイクロアレイを用いたシングルジーン分析のような先進的なプラットフォームに依存しています。セグメンテーションではさらに、適応症別にアプリケーションを区別し、がん適応症と非がん適応症に区別しています。がんセグメントでは、乳がん、大腸がん、肺がん、黒色腫、前立腺がんなど、それぞれ特定の診断上の注意を必要とする一般的な疾患がサブ分類に含まれます。その他の次元では、学術・研究センターから臨床診断ラボ、病院、医院ラボまで、エンドユーザー環境に焦点を当てています。最後に、アプリケーションのセグメンテーションは、早期がんスクリーニング、再発モニタリング、治療法選択、治療モニタリングなどのプロセスをカバーしており、これらすべてが包括的な患者管理戦略を支えています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんの罹患率が上昇し、早期診断法が必要となっている
    • 非侵襲的診断ツールの導入を支援する政府の取り組みと施策
  • 抑制要因
    • 循環腫瘍細胞の量の少なさと脆弱な性質に関連する懸念
  • 機会
    • リキッドバイオプシーセグメントにおけるがん研究の拡大のための資金提供
    • マイクロアレイと次世代シーケンス（NGS）の重要な活用
  • 課題
    • リキッドバイオプシー技術におけるデータプライバシーの懸念と倫理的問題
• 市場セグメンテーション分析
  • バイオマーカー：遺伝子変化の特定に多用途に使える遊離DNA（cfDNA）の重要な利用
  • サンプル：幅広い臨床応用と強力なデータサポートにより、血液ベースの液体生検の利用が増加
  • タイプ：がん症状の早期発見とスクリーニングのための検査キットの利用の進化
  • 技術：次世代シーケンス（NGS）を使用した複数遺伝子の並列分析が好まれるようになり、より高いスループットのデータが得られるようになった
  • 適応症：乳がんの有病率の高さから、乳がんに対するリキッドバイオプシー検査の需要が急増している
  • エンドユーザー：臨床診断ラボ全体でリキッドバイオプシーテストの使用が急増
  • 用途：早期がん検診におけるリキッドバイオプシーの指数関数的利用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 リキッドバイオプシー市場：バイオマーカー別

• イントロダクション
• 遊離DNA
• 循環腫瘍細胞
• 循環腫瘍DNA
• 細胞外小胞

第7章 リキッドバイオプシー市場：サンプル別

• イントロダクション
• 血液ベース
• 尿ベース

第8章 リキッドバイオプシー市場：タイプ別

• イントロダクション
• アッセイキット
• 機器
• サービス

第9章 リキッドバイオプシー市場：技術別

• イントロダクション
• NGSを用いた複数遺伝子並列分析
• PCRマイクロアレイを用いた単一遺伝子分析

第10章 リキッドバイオプシー市場：適応症別

• イントロダクション
• がんの適応
  • 乳がん
  • 大腸がん
  • 肺がん
  • 黒色腫
  • 前立腺がん
• 非がん適応症

第11章 リキッドバイオプシー市場：エンドユーザー別

• イントロダクション
• 学術研究センター
• 臨床診断ラボ
• 病院
• 医師のオフィスの検査室

第12章 リキッドバイオプシー市場：用途別

• イントロダクション
• 早期がん検診
• 再発モニタリング
• 治療法の選択
• 治療モニタリング

第13章 南北アメリカのリキッドバイオプシー市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋のリキッドバイオプシー市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカのリキッドバイオプシー市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ANGLE PLC
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Biocartis NV
• Danaher Corporation
• DiaCarta, Inc.
• Dxcover Limited
• Epic Sciences Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• GENCURIX
• Guardant Health, Inc.
• Illumina, Inc.
• Labcorp Holdings Inc.
• Laboratory Dr. med. Pachmann
• Lucence Health Inc.
• LungLife AI, Inc.
• MDxHealth SA
• Menarini Silicon Biosystems SpA
• Merck KGaA
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• OncoDNA SA
• PerkinElmer, Inc.
• Personalis, Inc.
• QIAGEN N.V.
• SAGA Diagnostics AB
• Strand Life Sciences Pvt Ltd.
• Sysmex Corporation
• Tempus AI, Inc.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. LIQUID BIOPSY MARKET MULTI-CURRENCY
• FIGURE 2. LIQUID BIOPSY MARKET MULTI-LANGUAGE
• FIGURE 3. LIQUID BIOPSY MARKET RESEARCH PROCESS
• FIGURE 4. LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 25. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 27. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 29. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 30. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 31. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LIQUID BIOPSY MARKET DYNAMICS
• TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 68. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 109. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 110. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. INDIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 117. INDIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 118. INDIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. INDIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. INDIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. INDIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. INDIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. INDIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. JAPAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. TAIWAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. THAILAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. VIETNAM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. DENMARK LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. EGYPT LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. FINLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 244. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 252. ISRAEL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 254. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 255. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 258. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 259. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. NIGERIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. NORWAY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 285. POLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 286. POLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 287. POLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 288. POLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 289. POLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 290. POLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 291. POLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 292. POLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 293. QATAR LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 294. QATAR LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 295. QATAR LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 296. QATAR LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 297. QATAR LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 298. QATAR LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 299. QATAR LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 300. QATAR LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 308. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 316. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 324. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 327. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 328. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 329. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 330. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 332. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 333. SWEDEN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 334. SWEDEN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 335. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 336. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 337. SWEDEN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 338. SWEDEN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 339. SWEDEN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 340. SWEDEN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 341. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 342. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 343. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 344. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 345. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 346. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 347. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 348. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 349. TURKEY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 350. TURKEY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 351. TURKEY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 352. TURKEY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 353. TURKEY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 354. TURKEY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 355. TURKEY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 356. TURKEY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 357. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 358. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 359. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 360. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 361. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 362. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 363. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 364. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 365. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
• TABLE 366. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
• TABLE 367. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 368. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 369. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 370. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
• TABLE 371. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 372. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 373. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 374. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

The Liquid Biopsy Market was valued at USD 6.00 billion in 2023 and is projected to grow to USD 6.72 billion in 2024, with a CAGR of 12.19%, reaching USD 13.44 billion by 2030.

Liquid biopsy has fundamentally redefined the landscape of diagnostic testing and personalized patient care. Over recent years, innovations in non-invasive diagnostics have set the stage for transformative change in how diseases, particularly cancer, are detected and monitored. This method, which relies on sampling and analyzing non-solid biological tissue, primarily blood, offers a viable alternative to traditional surgical biopsies. The evolution of liquid biopsy technology is driven by its ability to capture circulating biomarkers that provide real-time information about the disease state, enabling timely and targeted therapeutic interventions.

The scientific community has shown an increasing interest in leveraging this technique to overcome the limitations of conventional tissue biopsy, enhancing early detection and facilitating ongoing monitoring. With growing investment in research and development and the integration of high-precision analytical tools, the liquid biopsy market now stands at the convergence of clinical need and technological advancement. In addition to its applications in oncology, liquid biopsy is rapidly expanding its footprint into other areas of medicine, enabling more comprehensive diagnostic solutions. This analysis provides an in-depth look into the current state of the market, elucidating the trends, segmentation, regional insights, and major players who are driving this innovation forward.

Transformative Shifts in the Landscape of Liquid Biopsy

The liquid biopsy market is witnessing rapid transformation fueled by advancements in technology, evolving regulatory frameworks, and increasing demand for minimally invasive diagnostic procedures. Over the past few years, there has been a distinct shift away from traditional methods towards solutions that offer greater precision, faster turnaround times, and broader applicability. Improvements in high-throughput sequencing, data analytics, and automation have not only enhanced the sensitivity and specificity of test results but also made the procedures more cost-effective.

Industry stakeholders are embracing these changes as they seek to leverage the ability of liquid biopsies to capture dynamic genetic and epigenetic alterations. This shift is marked by proactive collaborations between research institutions, technology providers, and healthcare practitioners aimed at refining biomarker discovery and validation processes. Moreover, streamlined regulatory pathways have further accelerated the introduction of novel tools and assays into the clinical setting. As market adoption expands, so too does the competitive landscape, leading to an environment where continuous innovation and integration of multi-disciplinary expertise remain essential. The current momentum surrounding liquid biopsy illustrates a broader trend of adopting precision medicine as a standard practice in clinical diagnostics, ultimately contributing to improved patient outcomes and cost efficiencies across healthcare systems.

Key Segmentation Insights for a Nuanced Market Overview

A detailed segmentation of the liquid biopsy market reveals an intricate structure that supports a diversified approach to disease detection and management. One of the core dimensions of the analysis is based on biomarkers, which underscores the importance of Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles. This biomarker-based segmentation not only highlights the varied diagnostic capabilities but also emphasizes the specific molecular insights that each marker provides. Equally important is the segmentation based on sample type. The market is studied across methodologies that utilize Blood Based and Urine Based samples, supporting both convenience and clinical effectiveness.

Furthermore, the market is categorized by the type of products and services offered, encompassing Assay Kits, Instruments, and Services, each playing a unique role in driving diagnostic performance. Equally significant is the segmentation based on technology, which leans on advanced platforms such as Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays. The segmentation further differentiates applications by indication, distinguishing between Cancer Indication and Non-Cancer Indication. In the cancer segment, sub-classifications include prevalent conditions such as Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer, each requiring specific diagnostic attention. Other dimensions focus on end-user environments, ranging from Academic & Research Centers to Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories. Finally, the application segmentation covers processes such as Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring, all of which collectively underpin a comprehensive patient management strategy.

Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles.

Based on Sample, market is studied across Blood Based and Urine Based.

Based on Type, market is studied across Assay Kits, Instruments, and Services.

Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.

Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.

Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.

Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.

Key Regional Insights Shaping Market Dynamics

Geographical analysis reveals distinctive growth patterns and market dynamics across different regions. In the Americas, high healthcare expenditure and advanced technological adoption in diagnostic practices have fostered rapid market growth and innovation. The region has been instrumental in validating cutting-edge approaches to liquid biopsy, driven by a synergistic ecosystem of research institutions, biotech companies, and regulatory support.

In the combined region of Europe, Middle East & Africa, the market benefits from robust public healthcare systems and collaborative research efforts that bridge technology with clinical practice. Firms in these regions are increasingly investing in the development of assays and platforms tailored to local healthcare needs, thereby enhancing diagnostic access and efficacy. Asia-Pacific stands out as a key growth driver, with emerging economies spearheading investment in healthcare infrastructure and diagnostic technologies. Government initiatives and rapidly expanding insurance coverage are further catalyzing market expansion. Cultural shifts towards early disease detection, combined with increased awareness and adoption of preventive healthcare measures, are expected to propel this region into a leading market segment over the coming years. Such geographical diversity highlights the regional nuances that collectively contribute to the global narrative of the liquid biopsy revolution.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Steering Innovation and Competition

The competitive landscape in the liquid biopsy market is characterized by a blend of established industry giants and nimble innovators. Prominent market players such as ANGLE PLC, Bio-Rad Laboratories, Inc., and Bio-Techne Corporation have cemented their roles by continuously investing in new technologies and expanding their product portfolios. Biocartis NV and Danaher Corporation, along with DiaCarta, Inc. and Dxcover Limited, are also pivotal in driving forward the diagnostic capabilities of liquid biopsy through strategic collaborations and cutting-edge research.

Epic Sciences Inc. and Exact Sciences Corporation have distinguished themselves by developing assays that offer high sensitivity and specificity, thereby setting benchmarks for clinical outcomes. F. Hoffmann-La Roche Ltd. and GENCURIX have leveraged their extensive experience in diagnostics to integrate liquid biopsy into broader therapeutic management frameworks. Companies such as Guardant Health, Inc. and Illumina, Inc. are renowned for their state-of-the-art sequencing technologies, which have significantly advanced the liquid biopsy field. The market is further enriched by contributions from Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, and Lucence Health Inc., whose innovative solutions drive process improvements in sample analysis. LungLife AI, Inc. and MDxHealth SA are actively involved in the development of artificial intelligence tools that further enhance diagnostic precision, while players like Menarini Silicon Biosystems SpA, Merck KGaA, and Myriad Genetics, Inc. maintain strong research pipelines. Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc. round out the competitive spectrum by contributing critical research, robust analytical frameworks, and dynamic market strategies that collectively propel the industry toward sustained innovation and global influence.

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include ANGLE PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, Danaher Corporation, DiaCarta, Inc., Dxcover Limited, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENCURIX, Guardant Health, Inc., Illumina, Inc., Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems SpA, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to invest in furthering diagnostic research and technological innovation while integrating cross-functional collaboration with clinical practitioners to boost validation studies. Active engagement in strategic partnerships with both academia and technology developers will ensure that emerging trends and regulatory changes are effectively leveraged to maintain competitive advantage. Emphasis should be placed on diversifying product suites to include next-generation sequencing platforms and advanced amplification tools that cater to evolving market needs. Furthermore, leaders must continuously evaluate supply chain efficiencies and streamline operational processes to reduce time-to-market for new diagnostic tools. Adoption of digital analytics and data management solutions can also play a pivotal role in optimizing clinical decision-making and improving patient outcomes. By staying abreast of technological advancements and regional market trends, companies can secure a leading position in a rapidly evolving landscape.

Conclusion: Charting the Course for Future Success

In summary, the liquid biopsy market represents a dynamic intersection of technological innovation and clinical application. The comprehensive insights provided, categorized by biomarkers, sample types, product offerings, technologies, indications, end-user environments, and applications, underscore the evolving nature of diagnostics in the modern medical landscape. Regional and competitive analyses further highlight that success in this arena depends on the ability to integrate cutting-edge science with strategic execution. As the market continues to mature, ongoing innovation and adaptive strategies will be crucial in meeting the challenges of evolving disease profiles and regulatory environments. This analysis reaffirms that a proactive, research-driven approach remains central to leveraging the full potential of liquid biopsy applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer worldwide necessitating early diagnosis methods
    • 5.1.1.2. Supportive government initiatives and policies for the adoption of non-invasive diagnostic tools
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with low abundance and fragile nature of the circulating tumor cells
  • 5.1.3. Opportunities
    • 5.1.3.1. Availability of funding to expand cancer research in the field of liquid biopsy
    • 5.1.3.2. Significant use of microarrays and next-generation sequencing (NGS)
  • 5.1.4. Challenges
    • 5.1.4.1. Data privacy concerns and ethical issues in liquid biopsy technology
• 5.2. Market Segmentation Analysis
  • 5.2.1. Biomarkers: Significant utilization of cell-free DNA (cfDNA) versatile in identifying genetic changes
  • 5.2.2. Sample: Rising usage of blood-based liquid biopsies owing to their broad clinical applications and robust data support
  • 5.2.3. Type: Evolving usage of assay kits for early detection and screening of cancer symptoms
  • 5.2.4. Technology: Increasing preference for the multi-gene parallel analysis using next-generation sequencing (NGS), offering higher throughput data
  • 5.2.5. Indication: Burgeoning preference for liquid biopsy tests for breast cancer due to its high prevalence
  • 5.2.6. End-User: Proliferating usage of the liquid biopsy test across the clinical diagnostic laboratories
  • 5.2.7. Application: Exponential utilization of the liquid biopsy for early cancer screening
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Liquid Biopsy Market, by Biomarkers

• 6.1. Introduction
• 6.2. Cell-free DNA
• 6.3. Circulating Tumor Cells
• 6.4. Circulating Tumor DNA
• 6.5. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

• 7.1. Introduction
• 7.2. Blood Based
• 7.3. Urine Based

8. Liquid Biopsy Market, by Type

• 8.1. Introduction
• 8.2. Assay Kits
• 8.3. Instruments
• 8.4. Services

9. Liquid Biopsy Market, by Technology

• 9.1. Introduction
• 9.2. Multi-gene Parallel Analysis using NGS
• 9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

• 10.1. Introduction
• 10.2. Cancer Indication
  • 10.2.1. Breast Cancer
  • 10.2.2. Colorectal Cancer
  • 10.2.3. Lung Cancer
  • 10.2.4. Melanoma
  • 10.2.5. Prostate Cancer
• 10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

• 11.1. Introduction
• 11.2. Academic & Research Centers
• 11.3. Clinical Diagnostic Laboratories
• 11.4. Hospitals
• 11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

• 12.1. Introduction
• 12.2. Early Cancer Screening
• 12.3. Recurrence Monitoring
• 12.4. Therapy Selection
• 12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Liquid Biopsy Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Mayo Clinic and Lucence join forces to expand global liquid biopsy access
  • 16.3.2. PanGIA Biotech and Canary Oncoceutics partner to pioneer an AI-integrated urine-based liquid biopsy
  • 16.3.3. QIAGEN expands liquid biopsy automation portfolio
  • 16.3.4. Strand Life Sciences launches liquid biopsy test for improved cancer diagnosis
  • 16.3.5. Novigenix unveils an AI-powered multimodal liquid biopsy approach that integrates cfDNA analysis and mRNA immune profiling
  • 16.3.6. SOPHiA GENETICS partners with the European Liquid Biopsy Society to advance decentralized liquid biopsy solutions
  • 16.3.7. Hitachi High-Tech and Gencurix forge strategic partnership to revolutionize cancer molecular diagnostics through advanced liquid biopsy and digital reporting for personalized treatment decisions
  • 16.3.8. Personalis and Tempus partner to advance precision liquid biopsy diagnostics
  • 16.3.9. Renovaro Biosciences to acquire Cyclomics to transform liquid biopsy technology
  • 16.3.10. Myriad Genetics expands its oncology portfolio by acquiring Precise Tumor and Precise Liquid assays from Intermountain Precision Genomics
  • 16.3.11. Veracyte strengthens liquid biopsy platform with C2i Genomics acquisition
• 16.4. Strategy Analysis & Recommendation
  • 16.4.1. F. Hoffmann-La Roche Ltd.
  • 16.4.2. Illumina, Inc.
  • 16.4.3. QIAGEN N.V.
  • 16.4.4. Guardant Health, Inc.

Companies Mentioned

• 1. ANGLE PLC
• 2. Bio-Rad Laboratories, Inc.
• 3. Bio-Techne Corporation
• 4. Biocartis NV
• 5. Danaher Corporation
• 6. DiaCarta, Inc.
• 7. Dxcover Limited
• 8. Epic Sciences Inc.
• 9. Exact Sciences Corporation
• 10. F. Hoffmann-La Roche Ltd.
• 11. GENCURIX
• 12. Guardant Health, Inc.
• 13. Illumina, Inc.
• 14. Labcorp Holdings Inc.
• 15. Laboratory Dr. med. Pachmann
• 16. Lucence Health Inc.
• 17. LungLife AI, Inc.
• 18. MDxHealth SA
• 19. Menarini Silicon Biosystems SpA
• 20. Merck KGaA
• 21. Myriad Genetics, Inc.
• 22. Natera, Inc.
• 23. NeoGenomics Laboratories, Inc.
• 24. OncoDNA SA
• 25. PerkinElmer, Inc.
• 26. Personalis, Inc.
• 27. QIAGEN N.V.
• 28. SAGA Diagnostics AB
• 29. Strand Life Sciences Pvt Ltd.
• 30. Sysmex Corporation
• 31. Tempus AI, Inc.
• 32. Thermo Fisher Scientific Inc.